





#### **Third Joint Conference**

of the

**British HIV Association (BHIVA)** 

with the

British Association for Sexual Health and HIV (BASHH)

1-4 April 2014

Arena and Convention Centre · Liverpool

## THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014





## Dr John McSorley

North West London Hospitals NHS Trust

Feasibility and acceptability of a quadrivalent human papillomavirus (HPV 4) vaccination programme for young men who have sex with men (MSM)

Results from the first year

Dr John McSorley
North West London Hospitals NHS Trust

## HPV4 in young MSM: Background 1

- HPV 6 & 11 associated with anogenital warts
- HPV 16 & 18 with anogenital cancers

- Majority of adult MSM multiply infected
- prevalence range 0 to 20% MSM Teens & 20s

- Lifetime incidence anogenital warts MSM c20%
- Lifetime incidence of anogenital Ca in MSM x15
- x10 again if HIV +ve

## HPV4 in young MSM: Background 2

UK Schools programme HPV4 since Sept 2012

HPV4 vaccine is immunogenic in MSM (HIV - & +)

MSM increased risk of bacterial STI acquisition

MSM acquisition of HIV continues


#### HPV4: Young MSM (<27yrs) Care Bundle

| Time<br>(months) | Sexual history, Risk<br>Assessment, STI,<br>Checklist, Support | Hep<br>A & B | HPV4 | Time To Test<br>(Text/email) |
|------------------|----------------------------------------------------------------|--------------|------|------------------------------|
| 0                | Yes                                                            | Yes          | Yes  | Yes                          |
| 1                |                                                                | Yes          |      |                              |
| 2                | Yes                                                            |              | Yes  | Yes                          |
| 6                | Yes                                                            |              | Yes  | Yes                          |
| 9                | Yes                                                            |              |      | Yes                          |
| 12               | Yes                                                            |              |      | Yes                          |

## HPV4: Young MSM

| ELIGIBLE                          | n = 256       | 207 Homosexual 47 Bisexual 2 Transsexual                                   |
|-----------------------------------|---------------|----------------------------------------------------------------------------|
| DID NOT START                     | n = 55 (21%)  | 35 Homosexual<br>20 Bisexual<br>p = 0.003                                  |
| NOT OFFERED                       | n = 33 (13%)  | 20 Bi "no more"<br>13 No return                                            |
| DECLINED                          | n = 18 (4%)   | <ul><li>10 Not local</li><li>6 No reason</li><li>2 Anti- vaccine</li></ul> |
| ACCEPTED, Deferred did not return | n = 4 (2%)    |                                                                            |
| STARTED                           | n = 201 (79%) | <ul><li>172 Homosexual</li><li>20 Bisexual</li><li>2 Transsexual</li></ul> |

## HPV4: MSM Ethnicity Groupings as %



## HPV4: Outcomes: Hepatitis vaccination see POSTER 25 P Kuria et al

| Outcome                 | Total | Percentage |
|-------------------------|-------|------------|
| Documented 3+ Hep B vax | 162   | 80         |
| Documented Hep A vaxxn  | 171   | 85         |

## Results 1 year; HPV4 uptake & return

|              | Total<br>N = 201 | % of Total             |
|--------------|------------------|------------------------|
| Dose 1       | 201              | 100%                   |
| Dose 2       | 155              | 77%                    |
| Dose 3       | 98<br>(<60)      | 49%<br>(< <b>7</b> 9%) |
| TTT visit(s) | 78               | 79%                    |

# HPV4: Results at 1 year HPV4 and STIs (See Poster 229 Brook et al.)

|           | Bacterial STI diagnosed | % with STI |
|-----------|-------------------------|------------|
| Dose 1    | 72                      | 36%        |
| Dose 2    | 26                      | 17%        |
| Dose 3    | 14                      | 14%        |
| TTT visit | 14                      | 18%        |

10 question on-line survey

• **161/201** (80%) provided email to contact

• **83/161** (52%) contactable

• **83/201** (41%) eligible

completed it

How did you hear about the HPV4 vaccine?

• 85% A doctor or nurse in the clinic

15% Knew about it already

Did you receive enough information on HPV4

```
• Yes 93%
```

• No 7%

• Comment 11%

 "its sum kind of the most common disease that you can catch during sex"

Did/Do you have any concerns re HPV4?

- No 86%
- Yes 14%

- "Whether it was safe as it was new for me"
- "My parents were worried that it would encourage promiscuity"

- If you didn't complete, why not?
- 15(of 47) "non returners" responded
- 6 forgot
- 3 don't think it's necessary
- 2 didn't like the injection
- 3 can't get back
- 11 (60) "late" "I am coming back"

 Do you think HPV4 for young MSM is a good idea?

- Yes 99%
- No 0%
- Not sure 1%

 "It seems to be an important health issue that is being overlooked"

 If you had the vaccine are you happy with your decision?

- Yes 99%
- No 1%

- "No" said (I regret) "I didn't have the vaccine"
- (Hmmm yes you did & you had all 3 doses!)

Would you recommend HPV4 to others?

```
• Yes 100%
```

• No 0%

- "I have done so already"
- "Sure!:) We need to make the world a.. Better place. Right!:)"

## HPV4 in young MSM: Conclusion

- An HPV4 vaccination programme in young MSM is feasible and can achieve coverage commensurate with other catch up programmes
- HPV4 vaccination is highly acceptable to and valued by young MSM
- Vaccination can be a useful tool for early engagement of MSM with sexual health services
- Young MSM have high levels of ongoing sexual health and STI prevention needs

## HPV4 in young MSM

Thanks to the young MSM of Brent & Harrow And staff at

The Patrick Clements Centre Central Middlesex Hospital &

Department of GUM & HIV Northwick Park Hospital







#### **Third Joint Conference**

of the

**British HIV Association (BHIVA)** 

with the

British Association for Sexual Health and HIV (BASHH)

1-4 April 2014

Arena and Convention Centre · Liverpool



## HPV4: Young MSM

|                       | Number | Percentage |
|-----------------------|--------|------------|
| Total                 | 201    | 100        |
|                       |        |            |
| New to NWLH           | 118    | 59         |
|                       |        |            |
| First GUM Service     | 77     | 38         |
|                       |        |            |
| Once elsewhere        | 6      | 3          |
| Twice elsewhere       | 11     | 5          |
| 3+ elsewhere          | 107    | 53         |
|                       |        |            |
| Never had Hep B vaxxn | 104    | 52         |
| Never had Hep A vaxxn | 101    | 50         |